Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
13 nov. 2024 17h00 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
08 oct. 2024 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
19 sept. 2024 07h00 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
18 sept. 2024 07h00 HE
|
Vivos Therapeutics, Inc
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now...
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
14 août 2024 16h05 HE
|
Vivos Therapeutics, Inc
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting...
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
14 août 2024 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
27 juin 2024 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
12 juin 2024 07h30 HE
|
Vivos Therapeutics, Inc
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment...
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
14 mai 2024 16h05 HE
|
Vivos Therapeutics, Inc
Vivos Expanding its Revenue Generating InitiativesAs Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters ofYear Over Year Improvement Due to Successful Cost Cutting Initiatives ...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
14 mai 2024 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...